The Latest Breaking News from Novo Nordisk

Researchers found that semaglutide, compared with a placebo, didn't significantly increase depressive thoughts.

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

A rise in counterfeit versions of sought-after weight loss drug has led to a series of hospitalisations.

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

Some 17,600 people took part in the trial and were either prescribed Wegovy or a dummy drug

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance

Small pharmacies find difficulty in prescribing the drug due to Big Pharma restrictions on the industry. ‌

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….